ReNeuron Group plc (RNUGF)
RNUGF Stock Price Chart
Explore ReNeuron Group plc interactive price chart. Choose custom timeframes to analyze RNUGF price movements and trends.
RNUGF Company Profile
Discover essential business fundamentals and corporate details for ReNeuron Group plc (RNUGF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Apr 2007
Employees
26.00
Website
https://www.reneuron.comCEO
Iain Gladstone Ross BSc C.DIR, CH.D
Description
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
RNUGF Financial Timeline
Browse a chronological timeline of ReNeuron Group plc corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 11 Nov 2024
Earnings released on 21 Aug 2024
Earnings released on 30 Sept 2023
EPS came in at -$0.06 , while revenue for the quarter reached $190.96K .
Earnings released on 31 Mar 2023
EPS came in at -$0.05 , while revenue for the quarter reached $113.72K .
Earnings released on 30 Sept 2022
EPS came in at -$0.06 , while revenue for the quarter reached $484.59K .
Earnings released on 31 Mar 2022
EPS came in at -$0.10 surpassing the estimated -$0.15 by +30.99%, while revenue for the quarter reached $452.49K .
Earnings released on 30 Sept 2021
EPS came in at -$0.12 , while revenue for the quarter reached $78.35K .
Earnings released on 31 Mar 2021
EPS came in at -$0.10 surpassing the estimated -$0.18 by +40.99%, while revenue for the quarter reached $298.42K , missing expectations by -78.37%.
Stock split effective on 30 Nov 2020
Shares were split 1027 : 1000 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Sept 2020
EPS came in at -$0.28 , while revenue for the quarter reached $52.92K .
RNUGF Stock Performance
Access detailed RNUGF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.